| Drug Name |
Florbetapir f-18 |
| Drug ID |
BADD_D00907 |
| Description |
Florbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide that plays a key role in Alzheimer's Disease pathogenesis. Marketed as the product Amyvid, florbetapir 18F is indicated for positron emission tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.
The radionucleide fluorine-18 was chosen as it has a half life of 110 minutes allowing it to accumulate sufficiently in the brain before undergoing positon emission decay. |
| Indications and Usage |
Florbetapir 18F is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
V09AX05 |
| DrugBank ID |
DB09149
|
| KEGG ID |
D09617
|
| MeSH ID |
C545186
|
| PubChem ID |
24822371
|
| TTD Drug ID |
D09CGE
|
| NDC Product Code |
Not Available |
| Synonyms |
florbetapir | 2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-5-(4-methylaminostyryl)pyridine | 4-(2-(6-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzamide | Amyvid | 18F-AV-45 | florbetapir F 18 | florbetapir F18 |
